O	0	8	Impaired	Impaired	JJ	B-NP
B-Multi-tissue_structure	9	17	coronary	coronary	JJ	I-NP
I-Multi-tissue_structure	18	28	collateral	collateral	NN	I-NP
I-Multi-tissue_structure	29	35	vessel	vessel	NN	I-NP
O	36	47	development	development	NN	I-NP
O	48	50	in	in	IN	B-PP
O	51	59	patients	patient	NNS	B-NP
O	60	64	with	with	IN	B-PP
O	65	78	proliferative	proliferative	JJ	B-NP
O	79	87	diabetic	diabetic	JJ	I-NP
O	88	99	retinopathy	retinopathy	NN	I-NP
O	99	100	.	.	.	O

O	101	111	BACKGROUND	BACKGROUND	NN	B-NP
O	111	112	:	:	:	O
O	113	121	Diabetic	Diabetic	JJ	B-NP
O	122	130	patients	patient	NNS	I-NP
O	131	135	have	have	VBP	B-VP
O	136	140	been	be	VBN	I-VP
O	141	149	reported	report	VBN	I-VP
O	150	152	to	to	TO	I-VP
O	153	157	have	have	VB	I-VP
O	158	166	impaired	impair	VBN	I-VP
B-Multi-tissue_structure	167	175	coronary	coronary	JJ	B-NP
I-Multi-tissue_structure	176	186	collateral	collateral	NN	I-NP
I-Multi-tissue_structure	187	193	vessel	vessel	NN	I-NP
O	194	200	growth	growth	NN	I-NP
O	200	201	,	,	,	O
O	202	210	although	although	IN	B-SBAR
O	211	215	they	they	PRP	B-NP
O	216	220	have	have	VBP	B-VP
O	221	230	excessive	excessive	JJ	B-NP
O	231	249	neovascularization	neovascularization	NN	I-NP
O	250	252	in	in	IN	B-PP
O	253	256	the	the	DT	B-NP
B-Multi-tissue_structure	257	263	retina	retina	NN	I-NP
O	263	264	.	.	.	O

O	265	275	HYPOTHESIS	HYPOTHESIS	NN	B-NP
O	275	276	:	:	:	O
O	277	281	This	This	DT	B-NP
O	282	287	study	study	NN	I-NP
O	288	291	was	be	VBD	B-VP
O	292	300	designed	design	VBN	I-VP
O	301	303	to	to	TO	B-VP
O	304	311	compare	compare	VB	I-VP
B-Multi-tissue_structure	312	320	coronary	coronary	JJ	B-NP
I-Multi-tissue_structure	321	331	collateral	collateral	NN	I-NP
O	332	343	circulation	circulation	NN	I-NP
O	344	345	(	(	(	O
O	345	348	CCC	CCC	NN	B-NP
O	348	349	)	)	)	O
O	350	352	in	in	IN	B-PP
O	353	361	patients	patient	NNS	B-NP
O	362	366	with	with	IN	B-PP
O	367	380	proliferative	proliferative	JJ	B-NP
O	381	389	diabetic	diabetic	JJ	I-NP
O	390	401	retinopathy	retinopathy	NN	I-NP
O	402	403	(	(	(	O
O	403	406	PDR	PDR	NN	B-NP
O	406	407	)	)	)	O
O	408	412	with	with	IN	B-PP
O	413	417	that	that	DT	B-NP
O	418	420	in	in	IN	B-PP
O	421	429	patients	patient	NNS	B-NP
O	430	437	without	without	IN	B-PP
O	438	440	DR	DR	NN	B-NP
O	440	441	.	.	.	O

O	442	449	METHODS	METHODS	NNS	B-NP
O	449	450	:	:	:	O
O	451	457	Ninety	Ninety	CD	B-NP
O	458	466	diabetic	diabetic	JJ	I-NP
O	467	475	patients	patient	NNS	I-NP
O	476	480	with	with	IN	B-PP
O	481	488	chronic	chronic	JJ	B-NP
O	489	494	total	total	JJ	I-NP
O	495	504	occlusion	occlusion	NN	I-NP
O	505	507	in	in	IN	B-PP
O	508	510	at	at	IN	B-NP
O	511	516	least	least	JJS	I-NP
O	517	520	one	one	CD	I-NP
O	521	526	major	major	JJ	I-NP
B-Multi-tissue_structure	527	537	epicardial	epicardial	JJ	I-NP
I-Multi-tissue_structure	538	546	coronary	coronary	JJ	I-NP
I-Multi-tissue_structure	547	553	artery	artery	NN	I-NP
O	554	558	were	be	VBD	B-VP
O	559	567	enrolled	enrol	VBN	I-VP
O	568	570	in	in	IN	B-PP
O	571	574	the	the	DT	B-NP
O	575	580	study	study	NN	I-NP
O	580	581	.	.	.	O

O	582	588	Groups	Group	NNS	B-NP
O	589	590	1	1	CD	I-NP
O	591	594	and	and	CC	I-NP
O	595	596	2	2	CD	I-NP
O	597	606	consisted	consist	VBD	B-VP
O	607	609	of	of	IN	B-PP
O	610	612	48	48	CD	B-NP
O	613	621	patients	patient	NNS	I-NP
O	622	629	without	without	IN	B-PP
O	630	632	DR	DR	NN	B-NP
O	633	636	and	and	CC	O
O	637	639	42	42	CD	B-NP
O	640	648	patients	patient	NNS	I-NP
O	649	653	with	with	IN	B-PP
O	654	657	PDR	PDR	NN	B-NP
O	657	658	,	,	,	O
O	659	671	respectively	respectively	RB	B-ADVP
O	671	672	.	.	.	O

B-Multi-tissue_structure	673	681	Coronary	Coronary	JJ	B-NP
I-Multi-tissue_structure	682	692	collateral	collateral	NN	I-NP
O	693	704	circulation	circulation	NN	I-NP
O	705	706	(	(	(	O
O	706	709	CCC	CCC	NN	B-NP
O	709	710	)	)	)	O
O	711	714	was	be	VBD	B-VP
O	715	723	analyzed	analyze	VBN	I-VP
O	724	733	according	accord	VBG	B-PP
O	734	736	to	to	TO	B-PP
O	737	740	the	the	DT	B-NP
O	741	748	Rentrop	Rentrop	NNP	I-NP
O	749	755	system	system	NN	I-NP
O	755	756	.	.	.	O

O	757	761	Each	Each	DT	B-NP
O	762	767	group	group	NN	I-NP
O	768	771	was	be	VBD	B-VP
O	772	776	also	also	RB	I-VP
O	777	784	divided	divide	VBN	I-VP
O	785	789	into	into	IN	B-PP
O	790	793	two	two	CD	B-NP
O	794	803	subgroups	subgroup	NNS	I-NP
O	804	813	according	accord	VBG	B-PP
O	814	816	to	to	TO	B-PP
O	817	821	poor	poor	JJ	B-NP
O	822	825	and	and	CC	I-NP
O	826	830	good	good	JJ	I-NP
O	831	834	CCC	CCC	NN	I-NP
O	834	835	.	.	.	O

B-Organism_substance	836	841	Serum	Serum	NN	B-NP
O	842	850	vascular	vascular	JJ	I-NP
O	851	862	endothelial	endothelial	JJ	I-NP
O	863	869	growth	growth	NN	I-NP
O	870	876	factor	factor	NN	I-NP
O	877	878	(	(	(	O
O	878	882	VEGF	VEGF	NN	B-NP
O	882	883	)	)	)	O
O	884	890	levels	level	NNS	B-NP
O	891	895	were	be	VBD	B-VP
O	896	904	measured	measure	VBN	I-VP
O	905	910	using	use	VBG	B-VP
O	911	914	the	the	DT	B-NP
O	915	921	enzyme	enzyme	NN	I-NP
O	921	922	-	-	HYPH	B-VP
O	922	928	linked	link	VBN	B-NP
O	929	942	immunosorbent	immunosorbent	NN	I-NP
O	943	948	assay	assay	NN	I-NP
O	949	950	(	(	(	O
O	950	955	ELISA	ELISA	NN	B-NP
O	955	956	)	)	)	O
O	957	960	kit	kit	NN	B-NP
O	960	961	.	.	.	O

O	962	969	RESULTS	RESULTS	NNS	B-NP
O	969	970	:	:	:	O
O	971	974	The	The	DT	B-NP
O	975	979	mean	mean	JJ	I-NP
O	980	987	Rentrop	Rentrop	NNP	I-NP
O	988	998	collateral	collateral	NN	I-NP
O	999	1004	score	score	NN	I-NP
O	1005	1008	was	be	VBD	B-VP
O	1009	1015	higher	high	JJR	B-ADJP
O	1016	1018	in	in	IN	B-PP
O	1019	1024	Group	Group	NN	B-NP
O	1025	1026	1	1	CD	I-NP
O	1027	1031	than	than	IN	B-PP
O	1032	1034	in	in	IN	B-PP
O	1035	1040	Group	Group	NN	B-NP
O	1041	1042	2	2	CD	I-NP
O	1043	1044	(	(	(	O
O	1044	1045	2	2	CD	B-NP
O	1045	1046	.	.	SYM	I-NP
O	1046	1048	39	39	CD	I-NP
O	1049	1050	+	+	SYM	O
O	1050	1051	/	/	SYM	B-NP
O	1051	1052	-	-	SYM	B-NP
O	1053	1054	1	1	CD	I-NP
O	1054	1055	.	.	SYM	I-NP
O	1055	1057	07	07	CD	I-NP
O	1058	1060	vs	v	NNS	I-NP
O	1060	1061	.	.	.	O
O	1062	1063	1	1	CD	B-NP
O	1063	1064	.	.	.	I-NP
O	1064	1066	76	76	CD	I-NP
O	1067	1068	+	+	SYM	O
O	1068	1069	/	/	SYM	O
O	1069	1070	-	-	SYM	B-NP
O	1071	1072	0	0	CD	B-NP
O	1072	1073	.	.	SYM	I-NP
O	1073	1075	76	76	CD	I-NP
O	1075	1076	,	,	,	O
O	1077	1089	respectively	respectively	RB	B-ADVP
O	1089	1090	,	,	,	O
O	1091	1092	p	p	NN	B-NP
O	1094	1098	less	less	JJR	B-NP
O	1099	1103	than	than	IN	I-NP
O	1105	1106	0	0	CD	I-NP
O	1106	1107	.	.	.	I-NP
O	1107	1110	001	001	CD	I-NP
O	1110	1111	)	)	)	O
O	1111	1112	.	.	.	O

O	1113	1117	When	When	WRB	B-ADVP
O	1118	1121	the	the	DT	B-NP
O	1122	1125	two	two	CD	I-NP
O	1126	1132	groups	group	NNS	I-NP
O	1133	1137	were	be	VBD	B-VP
O	1138	1146	compared	compare	VBN	I-VP
O	1147	1151	with	with	IN	B-PP
O	1152	1159	respect	respect	NN	B-NP
O	1160	1162	to	to	TO	B-PP
O	1163	1167	poor	poor	JJ	B-NP
O	1168	1171	and	and	CC	I-NP
O	1172	1176	good	good	JJ	I-NP
O	1177	1180	CCC	CCC	NN	I-NP
O	1180	1181	,	,	,	O
O	1182	1186	poor	poor	JJ	B-NP
O	1187	1190	CCC	CCC	NN	I-NP
O	1191	1194	was	be	VBD	B-VP
O	1195	1201	higher	high	JJR	B-ADJP
O	1202	1204	in	in	IN	B-PP
O	1205	1213	patients	patient	NNS	B-NP
O	1214	1218	with	with	IN	B-PP
O	1219	1222	PDR	PDR	NN	B-NP
O	1223	1224	(	(	(	O
O	1224	1226	64	64	CD	B-NP
O	1227	1229	vs	v	NNS	I-NP
O	1229	1230	.	.	.	O
O	1231	1233	36	36	CD	B-NP
O	1233	1234	%	%	NN	I-NP
O	1234	1235	,	,	,	O
O	1236	1248	respectively	respectively	RB	B-ADVP
O	1248	1249	,	,	,	O
O	1250	1251	p	p	NN	B-NP
O	1252	1253	=	=	SYM	B-VP
O	1254	1255	0	0	CD	B-NP
O	1255	1256	.	.	SYM	I-NP
O	1256	1258	01	01	CD	I-NP
O	1258	1259	)	)	)	O
O	1259	1260	.	.	.	O

B-Organism_substance	1261	1266	Serum	Serum	NN	B-NP
O	1267	1271	VEGF	VEGF	NN	I-NP
O	1272	1278	levels	level	NNS	I-NP
O	1279	1283	were	be	VBD	B-VP
O	1284	1290	higher	high	JJR	B-ADJP
O	1291	1293	in	in	IN	B-PP
O	1294	1302	patients	patient	NNS	B-NP
O	1303	1307	with	with	IN	B-PP
O	1308	1311	PDR	PDR	NN	B-NP
O	1312	1316	than	than	IN	B-PP
O	1317	1319	in	in	IN	B-PP
O	1320	1325	those	those	DT	B-NP
O	1326	1333	without	without	IN	B-PP
O	1334	1336	DR	DR	NN	B-NP
O	1337	1338	(	(	(	O
O	1338	1341	219	219	CD	B-NP
O	1342	1343	+	+	SYM	O
O	1343	1344	/	/	SYM	O
O	1344	1345	-	-	SYM	O
O	1346	1348	99	99	CD	B-NP
O	1349	1351	vs	v	NNS	I-NP
O	1351	1352	.	.	.	O
O	1353	1356	139	139	CD	B-NP
O	1357	1358	+	+	SYM	O
O	1358	1359	/	/	SYM	O
O	1359	1360	-	-	SYM	O
O	1361	1363	98	98	CD	B-NP
O	1364	1366	pg	pg	NN	I-NP
O	1366	1367	/	/	SYM	O
O	1367	1369	ml	ml	NN	B-NP
O	1369	1370	,	,	,	O
O	1371	1372	p	p	NN	B-NP
O	1374	1378	less	less	JJR	B-NP
O	1379	1383	than	than	IN	I-NP
O	1385	1386	0	0	CD	I-NP
O	1386	1387	.	.	.	I-NP
O	1387	1390	001	001	CD	I-NP
O	1390	1391	)	)	)	O
O	1391	1392	;	;	:	O
O	1393	1400	however	however	RB	B-ADVP
O	1400	1401	,	,	,	O
O	1402	1410	patients	patient	NNS	B-NP
O	1411	1415	with	with	IN	B-PP
O	1416	1420	poor	poor	JJ	B-NP
O	1421	1424	and	and	CC	I-NP
O	1425	1429	good	good	JJ	I-NP
O	1430	1433	CCC	CCC	NN	I-NP
O	1434	1437	had	have	VBD	B-VP
O	1438	1445	similar	similar	JJ	B-NP
O	1446	1450	VEGF	VEGF	NN	I-NP
O	1451	1457	levels	level	NNS	I-NP
O	1457	1458	.	.	.	O

O	1459	1470	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1470	1471	:	:	:	O
O	1472	1474	We	We	PRP	B-NP
O	1475	1479	have	have	VBP	B-VP
O	1480	1485	shown	show	VBN	I-VP
O	1486	1490	that	that	IN	B-SBAR
O	1491	1499	patients	patient	NNS	B-NP
O	1500	1504	with	with	IN	B-PP
O	1505	1508	PDR	PDR	NN	B-NP
O	1509	1513	have	have	VBP	B-VP
O	1514	1515	a	a	DT	B-NP
O	1516	1521	lower	low	JJR	I-NP
B-Multi-tissue_structure	1522	1530	coronary	coronary	JJ	I-NP
I-Multi-tissue_structure	1531	1541	collateral	collateral	NN	I-NP
O	1542	1547	score	score	NN	I-NP
O	1548	1552	than	than	IN	B-PP
O	1553	1561	patients	patient	NNS	B-NP
O	1562	1569	without	without	IN	B-PP
O	1570	1572	DR	DR	NN	B-NP
O	1572	1573	.	.	.	O

O	1574	1578	Also	Also	RB	B-ADVP
O	1578	1579	,	,	,	O
B-Organism_substance	1580	1585	serum	serum	NN	B-NP
O	1586	1590	VEGF	VEGF	NN	I-NP
O	1591	1594	was	be	VBD	B-VP
O	1595	1608	significantly	significantly	RB	B-ADJP
O	1609	1615	higher	high	JJR	I-ADJP
O	1616	1618	in	in	IN	B-PP
O	1619	1627	patients	patient	NNS	B-NP
O	1628	1632	with	with	IN	B-PP
O	1633	1636	PDR	PDR	NN	B-NP
O	1637	1641	than	than	IN	B-PP
O	1642	1644	in	in	IN	B-PP
O	1645	1650	those	those	DT	B-NP
O	1651	1658	without	without	IN	B-PP
O	1659	1661	DR	DR	NN	B-NP
O	1661	1662	.	.	.	O

O	1663	1668	These	These	DT	B-NP
O	1669	1677	findings	finding	NNS	I-NP
O	1678	1682	have	have	VBP	B-VP
O	1683	1692	suggested	suggest	VBN	I-VP
O	1693	1697	that	that	IN	B-SBAR
O	1698	1706	diabetes	diabetes	NN	B-NP
O	1707	1715	mellitus	mellitus	NN	I-NP
O	1716	1719	may	may	MD	B-VP
O	1720	1724	have	have	VB	I-VP
O	1725	1726	a	a	DT	B-NP
O	1727	1736	different	different	JJ	I-NP
O	1737	1743	action	action	NN	I-NP
O	1744	1746	on	on	IN	B-PP
B-Multi-tissue_structure	1747	1754	retinal	retinal	JJ	B-NP
O	1755	1758	and	and	CC	I-NP
B-Multi-tissue_structure	1759	1767	coronary	coronary	JJ	I-NP
O	1768	1779	circulation	circulation	NN	I-NP
O	1779	1780	.	.	.	O

